FMP

FMP

Enter

AMPH - Amphastar Pharmaceut...

photo-url-https://images.financialmodelingprep.com/symbol/AMPH.png

Amphastar Pharmaceuticals, Inc.

AMPH

NASDAQ

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

35.7 USD

0.04 (0.112%)

Latest AMPH News

Seeking Alpha

Aug 19, 2024

6 Beaten Down Stocks Rated Buy (SA Quant)

The three-week market selloff sparked by recession fears was led by plunging tech, cyclical, industrial, and energy stocks. High-quality stocks clobbered in the past 30 days, and others beaten down in the past year offer potential buying opportunities. We identified 6 stocks down by double digits within the last year with Buy or Strong Buy Quant Ratings, high forward growth metrics, and attractive valuations.

Read More

Zacks Investment Research

Aug 7, 2024

Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics

The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Read More

Zacks Investment Research

Aug 7, 2024

Amphastar Pharmaceuticals (AMPH) Tops Q2 Earnings and Revenue Estimates

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.65 per share a year ago.

Read More

Zacks Investment Research

Jul 15, 2024

Why Amphastar (AMPH) is Poised to Beat Earnings Estimates Again

Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Read More

Zacks Investment Research

Jul 10, 2024

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY, and TEVA.

Read More

InvestorPlace

Jun 24, 2024

7 Biotech Stocks to Buy on the Dip: June 2024

Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it's important to save money and invest for the future.

Read More

MarketBeat

Jun 18, 2024

Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts

Will the market get interest rate cuts at all this year? That is the question that looms over most investors' shoulders today.

Read More

Accesswire

Jun 3, 2024

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / June 3, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 pm EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

Read More

Seeking Alpha

May 30, 2024

Amphastar Pharmaceuticals: Buy When Fear Is Overblown

Seeking Alpha's screener identified Amphastar Pharmaceuticals as a potential investment candidate based on its solid financials, positive growth in revenue and earnings. Despite its strong financials and potential for earnings growth, the company's stock fell 31% in 5 months. The article aims to uncover the reasons behind the price decline to determine if the price decline is a temporary setback that offers an opportunity for value investors.

Read More

InvestorPlace

May 16, 2024

Patent Peril: 3 Stocks at Risk From the FTC's Drug Crusade

Several drug stocks are at risk as the Federal Trade Commission is going after pharmaceutical companies that it alleges are trying to keep generic drugs at bay from their branded products. The Biden administration is attacking businesses across the board, such as its recent assault on the oil industry.

Read More
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep